Last updated: February 13, 2026
Overview
NDC 69452-0161 corresponds to Adalimumab, a biosimilar approved by the FDA in 2022. It is a follow-on biologic used for autoimmune diseases including rheumatoid arthritis, Crohn’s disease, and psoriasis. As a biosimilar, it enters a highly competitive market with established biologics and multiple biosimilars.
Market Size and Penetration
- The total biologics market for autoimmune indications reached approximately $65 billion in 2022, with Adalimumab constituting nearly 65% of U.S. biologic sales ([1]).
- The biosimilars market for adalimumab started growing after the first biosimilar approval in 2021. By mid-2023, biosimilars captured about 25% of the adalimumab market share ([2]).
- The primary competitors include Humira (AbbVie), Amjevita (Amgen), and Hyrimoz (Sandoz). These competitors modulate prices and market share.
Pricing Dynamics
- The originator, Humira, had an list price of approximately $6,800 per 40mg pre-subsidy per injection in 2022.
- Biosimilar prices tend to be 15-30% below the originator. Current biosimilar prices range from $4,200 to $5,200 per 40mg dose ([3], [4]).
- Actual patient payers see variable discounts and rebates; commercial insurers often negotiate rebates of 20-30%, reducing net prices further.
Market Entry and Pricing Trends
- Early biosimilar entrants average initial discounts of around 20% compared to the originator.
- Over two years, biosimilar prices tend to stabilize at about 20-25% below originator levels.
- Patent litigations and market access strategies influence price stability and market share growth.
Price Projection (2023-2027)
| Year |
Estimated Average Price (per 40mg dose) |
Market Share |
Revenue Projection |
Key Influencing Factors |
| 2023 |
$4,500 |
25% |
$1.4 billion |
Entry of biosimilar; rebates; rebate negotiations |
| 2024 |
$4,500 |
35% |
$2.0 billion |
Increased adoption; competitive discounts |
| 2025 |
$4,200 |
45% |
$2.6 billion |
Market consolidation; pricing stabilization |
| 2026 |
$4,200 |
55% |
$3.3 billion |
Expanded formulary coverage |
| 2027 |
$4,000 |
60% |
$3.6 billion |
Increased biosimilar penetration |
Prices are expected to decline moderately as biosimilar market penetration increases, with ongoing negotiations and rebate strategies affecting net prices.
Regulatory and Policy Impact
- CMS and commercial payers increasingly favor biosimilars, promoting their usage through formulary placement and reduced co-pays.
- Patent litigations could delay or accelerate market entry of new biosimilars, influencing price dynamics.
- U.S. biosimilar approval and market access are also shaped by FDA policies encouraging biosimilar uptake.
Key Takeaways
- NDC 69452-0161 (Adalimumab biosimilar) entered a competitive market with firm price reductions expected.
- Prices are projected to decline from approximately $4,500 in 2023 to about $4,000 by 2027.
- Biosimilar market share is expected to rise to around 60%, driven by payer policies and market consolidation.
- Total revenue for the biosimilar could reach approximately $3.6 billion in 2027, up from $1.4 billion in 2023, assuming current market dynamics.
FAQs
-
What factors most influence biosimilar pricing for adalimumab?
Rebate negotiations, patent disputes, market share, and payer policies significantly impact net prices.
-
How does biosimilar adoption affect original biologic revenues?
Increased biosimilar usage decreases revenue for the originator, potentially leading to price erosion and market share loss.
-
Are international markets relevant for this biosimilar?
Yes, biosimilar prices and uptake vary across countries due to regulatory, pricing, and reimbursement differences.
-
What is the typical timeline for biosimilar market penetration?
Market share growth from initial entry to stabilization typically spans 2-4 years.
-
How might future patent litigation impact prices?
Patent disputes can either delay biosimilar entry, maintaining higher prices, or accelerate entry if settled favorably.
Sources
- IQVIA, 2022.
- Evaluate Pharma, 2023.
- GoodRx, 2023.
- The Pharmaceutical Journal, 2022.
